You are here

Article Text

Article menu
Download PDFPDF
CASE REPORT
Lamellar macular hole after intravitreal ocriplasmin injection
  1. Ross Bronson Chod1,
  2. Clifford Goodrich1,
  3. Sandeep Saxena2,
  4. Levent Akduman1
  1. 1Department of Ophthalmology, St Louis University Eye Institute, St Louis, Missouri, USA
  2. 2Department of Ophthalmology, CSM Medical University, Lucknow, Uttar Pradesh, India
  1. Correspondence to Dr Levent Akduman, akdumanlevent{at}gmail.com

Summary

Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.

http://dx.doi.org/10.1136/bcr-2014-207810

Statistics from Altmetric.com

    View Full Text

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    2015 BMJ Publishing Group Ltd